New drug navenibart aims to tame hereditary swelling attacks
Disease control
Completed
This early trial tested a new drug called navenibart in 29 people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. Participants received one or two doses of the drug to check its safety and how well it might reduce attacks. The study is …
Phase: PHASE1, PHASE2 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC